Mostrar el registro sencillo del ítem

Alterations in the levels of growth factors in adolescents with major depressive disorder: a longitudinal study during the treatment with fluoxetine

dc.creatorBecerril-Villanueva, Enriquees_ES
dc.creatorPérez-Sánchez, Gilbertoes_ES
dc.creatorAlavarez-Herrera, Samanthaes_ES
dc.creatorGirón-Pérez, Manuel Ivánes_ES
dc.creatorArreola, Rodrigoes_ES
dc.creatorCruz-Fuentes, Carloses_ES
dc.creatorPalacios, Linoes_ES
dc.creatorDe la Peña, Francisco R.es_ES
dc.creatorPavón, Lenines_ES
dc.date2019
dc.date.accessioned2022-12-07T16:03:09Z
dc.date.available2022-12-07T16:03:09Z
dc.date.issued2019
dc.identifierJC21NC22es_ES
dc.identifier.issn0962-9351
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/7644
dc.identifier.urihttps://doi.org/10.1155/2019/9130868
dc.descriptionMajor depressive disorder (MDD) has a prevalence of 5% in adolescents. Several studies have described the association between the inflammatory response and MDD, but little is known about the relationship between MDD and growth factors, such as IL-7, IL-9, IL-17A, VEGF, basic FGF, G-CSF, and GM-CSF. It must be appointed that there are scarce reports on growth factors in adolescents with MDD and even fewer with a clinical follow-up. In this work, we evaluated the levels of growth factors (IL-7, IL-9, IL-17A, VEGF, basic FGF, G-CSF, and GM-CSF) in MDD adolescents and the clinical follow-up during eight weeks of treatment with fluoxetine. Methods. All patients were diagnosed according to the DSM-IV-TR, and the severity of the symptoms was evaluated using the Hamilton Depression Rating Scale (HDRS). Growth factors IL-7, IL-9, IL-17A, VEGF, basic FGF, G-CSF, and GM-CSF were quantified by cytometric bead array using serum samples from 22 adolescents with MDD and 18 healthy volunteers. Results. All patients showed clinical improvement since the fourth week of pharmacological treatment according to the HDRS. Considerably higher levels of IL-7, IL-9, IL-17A, VEGF, basic FGF, G-CSF, and GM-CSF were detected in MDD adolescents as compared to healthy volunteers. A significant but temporal decrease was detected in basic FGF, G-CSF, and GM-CSF at week four of fluoxetine administration. Conclusions. To the best of our knowledge, this is the first report to show alterations in the levels of growth factors, such as IL-7, IL-9, IL-17A, VEGF, basic FGF, G-CSF, and GM-CSF in MDD adolescents during eight weeks of clinical follow-up. These disturbances might be involved in the physiopathology of MDD since such growth factors have been proven to participate in the neural development and correct functioning of the CNS; therefore, subtle alterations in it may contribute to MDD.es_ES
dc.formatPDFes_ES
dc.language.isoenges_ES
dc.publisherHindawi Pub. Corpes_ES
dc.relation2019:9130868
dc.rightsAcceso Cerradoes_ES
dc.titleAlterations in the levels of growth factors in adolescents with major depressive disorder: a longitudinal study during the treatment with fluoxetinees_ES
dc.typeArtículoes_ES
dc.contributor.affiliationLaboratory of Psychoimmunology, National Institute of Psychiatry, “Ramón de la Fuente”, Calzada México-Xochimilco 101, Colonia San Lorenzo Huipulco, Tlalpan, 14370 México City, Mexico
dc.contributor.emaillkuriaki@imp.edu.mx (Pavón, Lenin)
dc.relation.jnabreviadoMEDIATORS INFLAMM
dc.relation.journalMediators of Inflammation
dc.identifier.placeEstados Unidos
dc.date.published2019
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.eissn1466-1861
dc.identifier.doi10.1155/2019/9130868


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem